Philippe Soubeyran
Aix-Marseille Univ,
Inserm,
CNRS,
Aix-Marseille Univ, INSERM, CNRS
Institut Paoli-Calmettes, CRCM
Philippe Soubeyran obtained his PhD from the Aix-Marseille University in 2000. At this time, his work was dedicated to the study of two homeotic genes, CDX1 and CDX2, involved in gut development and under-expressed in colon cancers. From 2000 to 2003, he worked as a postdoc at the Ludwig Institute for Cancer Research of Uppsala (Sweden) in the group of Prof. Ivan Dikic. The main goals of this training was to decipher the role of two scaffold proteins, CIN85 and ArgBP2, in the transduction and regulation of cell signaling. In 2005, he was recruited by the French National Institute for Health and Medical Research (INSERM) to work as a principal investigator in the Cellular Stress laboratory, from 2005 to 2012. Since 2012, he is a member of the Pancreatic Cancer team of CRCM (Cancer Research Center of Marseille). His current projects are dedicated to the identification of new resistance mechanisms of pancreatic cancer cells involving alterations of post-translational modifications of ubiquitin-like type.
Oligomerization and phosphorylation dependent regulation of ArgBP2 adaptive capabilities and associated functions.
PloS one , 2014 | Pubmed ID: 24475245
Tropheryma whipplei, the agent of Whipple's disease, affects the early to late phagosome transition and survives in a Rab5- and Rab7-positive compartment.
PloS one , 2014 | Pubmed ID: 24586722
Identification of new mechanisms of cellular response to chemotherapy by tracking changes in post-translational modifications by ubiquitin and ubiquitin-like proteins.
Journal of proteome research May, 2014 | Pubmed ID: 24654937
Redox-sensitive TP53INP1 SUMOylation as an oxidative stress sensor to activate TP53.
Molecular & cellular oncology Jul-Sep, 2014 | Pubmed ID: 27308354
Regulation of NUB1 Activity through Non-Proteolytic Mdm2-Mediated Ubiquitination.
PloS one , 2017 | Pubmed ID: 28099510
Chloroquine plays a cell-dependent role in the response to treatment of pancreatic adenocarcinoma.
Oncotarget Jul, 2018 | Pubmed ID: 30112111
Inactivation of NUPR1 promotes cell death by coupling ER-stress responses with necrosis.
Scientific reports 11, 2018 | Pubmed ID: 30451898
Ribonuclease MCPiP1 contributes to the loss of micro-RNA-200 family members in pancreatic cancer cells.
Oncotarget Nov, 2018 | Pubmed ID: 30542509
Pancreatic cancer chemo-resistance is driven by tumor phenotype rather than tumor genotype.
Heliyon Dec, 2018 | Pubmed ID: 30582059
Ligand-based design identifies a potent NUPR1 inhibitor exerting anticancer activity via necroptosis.
The Journal of clinical investigation 03, 2019 | Pubmed ID: 30920390
JoVEについて
Copyright © 2023 MyJoVE Corporation. All rights reserved